Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' trial achieved primary and secondary endpoints, showing improvements in liver function and key NASH biomarkers. The results reinforce rencofilstat's antifibrotic mode of action and increase confidence for the ongoing Phase 2b 'ASCEND-NASH' trial.
May 22, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hepion Pharmaceuticals' successful Phase 2 'ALTITUDE-NASH' trial results may positively impact the company's stock price in the short term.
The successful results of the Phase 2 'ALTITUDE-NASH' trial demonstrate the effectiveness of Hepion Pharmaceuticals' rencofilstat in treating NASH. This increases the likelihood of positive outcomes in the ongoing Phase 2b 'ASCEND-NASH' trial, which may lead to increased investor confidence and a potential short-term boost in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100